CTLA4 and cancer: In consideration of the important role of checkpoint inhibitor cancer immunotherapy, the difference in immune checkpoint expression was compared between low-and high-risk groups, and it was discovered that there was a substantial difference in the expressions of PD1, PDL-1 and CTLA4 between two groups (Figure 7C).